Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial

Схожие документы

• Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
  по: Xiaotong Li, et al.
  Опубликовано: (2019-04-01)
• Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
  по: Powles, Ryan L., et al.
  Опубликовано: (2020)
• Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial
  по: Pelekanou, Vasiliki, et al.
  Опубликовано: (2018)
• Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
  по: Casadevall, David, et al.
  Опубликовано: (2019)
• SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
  по: Nahleh, Z. A., et al.
  Опубликовано: (2016)